Curated News
By: NewsRamp Editorial Staff
April 17, 2025
Kairos Pharma Receives $876K DoD Award for ENV105 Trial Research
TLDR
- Kairos Pharma receives $876,000 for biomarker research in lung cancer, enhancing targeted therapy potential.
- Funding supports Cedars-Sinai Medical Center to identify patients for benefits from early intervention with ENV105 in Phase 1 trial.
- Kairos Pharma aims to improve cancer treatment outcomes through precise monitoring and targeted therapy, offering hope to patients.
- ENV105 antibody targets CD105 protein in cancer therapy, addressing drug resistance and disease relapse for better treatment efficacy.
Impact - Why it Matters
This news highlights the innovative research being conducted by Kairos Pharma to address drug resistance in cancer treatment, potentially leading to improved outcomes for patients with non-small cell lung cancer and prostate cancer. The funding from the U.S. Department of Defense underscores the importance of precision medicine in developing targeted therapies for patients with specific genetic mutations.
Summary
Kairos Pharma announced that the U.S. Department of Defense has awarded $876,000 to Cedars-Sinai Medical Center to support biomarker research for Kairos’ Phase 1 trial of ENV105 in EGFR-driven non-small cell lung cancer.
The study aims to identify patients developing resistance to osimertinib who may benefit from early intervention with ENV105, aligning with Kairos’ strategy to improve outcomes through targeted therapy.
ENV105 is in a Phase 2 clinical trial for castrate resistant prostate cancer and a Phase 1 trial for lung cancer, addressing significant unmet medical needs.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Kairos Pharma Receives $876K DoD Award for ENV105 Trial Research
